Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats

Endocrine-Related Cancer

Volumn 16, Issue 1, 2009, Pages 99-111

  Samuelson, Emma ^a   Hedberg, Carola ^a   Nilsson, Staffan ^b   Behboudi, Afrouz ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERFERON REGULATORY FACTOR 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P53; UVOMORULIN; CADHERIN; CATNB PROTEIN, RAT; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ERBB2 PROTEIN, RAT; GLYCOPROTEIN; IRF1 PROTEIN, RAT; PTEN PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SEQUENCE; INBRED STRAIN; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; RAT STRAIN; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; ADENOCARCINOMA; ALLELE; ANIMAL; CLASSIFICATION; ENDOMETRIUM; ENDOMETRIUM TUMOR; GENETICS; MALE; MUTATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ALLELES; ANIMALS; BETA CATENIN; CADHERINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; INTERFERON REGULATORY FACTOR-1; MALE; MUTATION; PTEN PHOSPHOHYDROLASE; RATS; RATS, INBRED STRAINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 65549161901     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0185     Document Type: Article

References (69)

1. Adamovic T, Trossö F, Roshani L, Andersson L, Petersen G, Rajaei S, Helou K & Levan G 2005 Oncogene amplification in the proximal part of chromosome 6 in rat endometrial adenocarcinomas as revealed by combined BAC/PAC FISH analysis, chromosome painting, zoo-FISH and allelotyping analysis. Genes, Chromosomes and Cancer 44 139-154.
2. Adamovic T, Hamta A, Roshani L, Lü X, Röhme D, Helou K, Klinga-Levan K & Levan G 2008 Rearrangement and allelic imbalance on chromosome 5 leads to homozygous deletions in the CDKN2A/2B tumor suppressor gene region in rat endometrial cancer. Cancer Genetics and Cytogenetics 184 9-21.
3. Aitman TJ, Critser JK, Cuppen E, Dominiczak A, Fernandez-Suarez XM, Flint J, Gauguier D, Geurts AM, Gould M, Harris PC et al. 2008 Progress and prospects in rat genetics: a community view. Nature Genetics 40 516-522.
4. Behboudi A, Levan G, Hedrich HJ & Klinga-Levan K 2001 High-density marker loss of heterozygosity analysis of rat chromosome 10 in endometrial adenocarcinoma. Genes, Chromosomes and Cancer 32 330-341.
5. Behboudi A, Roshani L, Kost-Alimova M, Montelius-Alatalo K, Röhme D, Klinga-Levan K & Ståhl F 2002 Detailed chromosomal and radiation hybrid mapping in the proximal part of rat chromosome 10 and gene order comparison with mouse and human. Mammalian Genome 13 302-309.
6. Carcangiu ML & Chambers JT 1992 Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecologic Oncology 47 298-305.
7. Catasus L, Machin P, Matias-Guiu X & Prat J 1998 Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Human Pathology 29 1160-1164.
8. Cavanagh D, Fiorica JV, Hoffman MS, Durfee J & Nicosia SV 1999 Adenocarcinoma of the endometrium: an institutional review. Cancer Control 6 354-360.
9. Di Cristofano A, Pesce B, Cordon-Cardo C & Pandolfi PP 1998 Pten is essential for embryonic development and tumour suppression. Nature Genetics 19 348-355.
10. Deerberg F & Kaspareit J 1987 Endometrial carcinoma in BDII/Han rats: model of a spontaneous hormonedependent tumor. Journal of the National Cancer Institute 78 1245-1251.
11. Deerberg F, Pohlmeyer G, Lörcher K & Petrow V 1995 Total suppression of spontaneous endometrial carcinoma inBDII/Han rats by melengestrol acetate. Oncology 52 319-325.
12. Esteller M, Xercavins J & Reventos J 1999 Advances in the molecular genetics of endometrial cancer (review). Oncology Reports 6 1377-1382.
13. Gelderman KA, Hultqvist M, Olsson LM, Bauer K, Pizzolla A, Olofsson P & Holmdahl R 2007 Rheumatoid arthritis: the role of reactive oxygen species in disease development and therapeutic strategies. Antioxidants & Redox Signaling 9 1541-1567.
14. Giatromanolaki A, Koukourakis MI, Ritis K, Mimidis K & Sivridis E 2004 Interferon regulatory factor-1 (IRF-1) suppression and derepression during endometrial tumorigenesis and cancer progression. Cytokine 26 164-168.
15. Green WB, Slovak ML, Chen IM, Pallavicini M, Hecht JL & Willman CL 1999 Lack of IRF-1 expression in acute promyelocytic leukemia and in a subset of acute myeloid leukemias with del(5)(q31). Leukemia 13 1960-1971.
16. Gruber SB & Thompson WD 1996 A population-based study of endometrial cancer and familial risk in younger women. Cancer and steroid hormone study group. Cancer Epidemiology, Biomarkers and Prevention 5 411-417.
17. Harima Y, Sawada S, Nagata K, Sougawa M, Ostapenko V & Ohnishi T 2001 Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy. International Journal of Oncology 18 493-497.
18. Hecht JL & Mutter GL 2006 Molecular and pathologic aspects of endometrial carcinogenesis. Journal of Clinical Oncology 24 4783-4791.
19. Helou K, Walentinsson A, Beckmann B, Johansson Å, Hedrich HJ, Szpirer C, Klinga-Levan K & Levan G 2001 Analysis of genetic changes in rat endometrial carcinomas by means of comparative genome hybridization. Cancer Genetics and Cytogenetics 127 118-127.
20. Jabbour HN, Critchley HO, Yu-Lee LY & Boddy SC 1999 Localization of interferon regulatory factor-1 (IRF-1) in nonpregnant human endometrium: expression of IRF-1 is up-regulated by prolactin during the secretory phase of the menstrual cycle. Journal of Clinical Endocrinology and Metabolism 84 4260-4265.
21. Jiang BH & Liu LZ 2008 PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochimica et Biophysica Acta 1784 150-158.
22. Kariola R, Abdel-Rahman WM, Ollikainen M, Butzow R, Peltomäki P & Nyström M 2005 APC and brta-catenin protein expression patters in HNPCC-related endometrial and colorectal cancers. Familial Cancer 4 187-190.
23. KarlssonÅ, Helou K, Walentinsson A, Hedrich HJ, Szpirer C & Levan G 2001 Amplification of Mycn, Ddx1, Rrm2, and Odc1 in rat uterine endometrial carcinomas. Genes, Chromosomes and Cancer 31 345-356.
24. Karlsson S, Holmberg E, Askerlund A & Levan KK 2007 Altered transforming growth factor-beta pathway expression pattern in rat endometrial cancer. Cancer Genetics and Cytogenetics 177 43-50.
25. Kaspareit-Rittinghausen J, Deerberg F & Rapp K 1987 Mortality and incidence of spontaneous neoplasms in BDII/Han rats. Zeitschrift für Versuchstierkunde 30 209-216.
26. Kolasa IK, Rembiszewska A, Janiec-Jankowska A, Dansonka-Mieszkowska A, Lewandowska AM, Konopka B & Kupryjan'czyk J 2006 PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecologic Oncology 103 692-697.
27. Konopka B, Paszko Z, Janiec-Jankowska A & Goluda M 2002 Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Cancer Letters 178 43-51.
28. Kroger A, Koster M, Schroeder K, Hauser H & Mueller PP 2002 Activities of IRF-1. Journal of Interferon & Cytokine Research 22 5-14.
29. Kuroboshi H, Okubo T, Kitaya K, Nakayama T, Daikoku N, Fushiki S & Honjo H 2003 Interferon regulatory factor-1 expression in human uterine endometrial carcinoma. Gynecologic Oncology 91 354-358.
30. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N & Ittmann M 2001 Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. PNAS 98 11563-11568.
31. Kwon CH, Zhao D, Chen J, Alcantara S, Li Y, Burns DK, Mason RP, Lee EY, Wu H & Parada LF 2008 Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Research 68 3286-3294.
32. Latta E & Chapman WB 2002 PTEN mutations and evolving concepts in endometrial neoplasia. Current Opinion in Obstetrics and Gynecology 14 59-65.
33. Lax SF 2004 Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Archiv 444 213-223.
34. Lax SF 2007 Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 39 46-54.
35. Li DM & Sun H 1998 PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. PNAS 95 15406-15411.
36. Liu FS 2007 Molecular carcinogenesis of endometrial cancer. Taiwanese Journal of Obstetrics & Gynecology 46 26-32.
37. Logan CY & Nusse R 2004 The Wnt signaling pathway in development and disease. Annual Review of Cell and Developmental Biology 20 781-810.
38. Lynch HT & de la Chapelle A 1999 Genetic susceptibility to non-polyposis colorectal cancer. Journal of Medical Genetics 36 801-818.
39. Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M & Mori T 1997 Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nature Genetics 17 271-272.
40. Nordlander C, Behboudi A, Levan G & Klinga-Levan K 2005 Allelic imbalance on chromosome 10 in rat endometrial adenocarcinomas. Cancer Genetics and Cytogenetics 156 158-166.
41. Nordlander C, Karlsson S, Karlsson Å, Sjöling Å, Winnes M, Klinga-Levan K & Behboudi A 2007 Analysis of chromosome 10 aberrations in rat endometrial cancer - evidence for a tumor suppressor locus distal to Tp53. International Journal of Cancer 120 1472-1481.
42. Ogasawara S, Tamura G, Maesawa C, Suzuki Y, Ishida K, Satoh N, Uesugi N, Saito K & Satodate R 1996 Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. Gastroenterology 110 52-57.
43. Ollikainen M, Abdel-Rahman WM, Lindroos A, Kariola R, Järvelä I, Pöyhönen M, Butzow R & Peltomäki P 2005 Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? Journal of Clinical Endocrinology 23 4609-4616.
44. Palacios J, Catasús L, Moreno-Bueno G, Matias-Guiu X, Prat J & Gamallo C 2001 Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. Virchows Archiv 438 464-469.
45. Parc YR, Halling KC, Burgart LJ, McDonnell SK, Schaid DJ, Thibodeau SN & Halling AC 2000 Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: associations with family history and histopathology. International Journal of Cancer 86 60-66.
46. Peltomaki P & Vasen HF 1997 The International Collaborative Group on HNPCC. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. Gastroenterology 113 1146-1158.
47. Planchon SM, Waite KA & Eng C 2008 The nuclear affairs of PTEN. Journal of Cell Science 121 249-253.
48. Pravenec M & Kurtz TW 2007 Molecular genetics of experimental hypertension and the metabolic syndrome: from gene pathways to new therapies. Hypertension 49 941-952.
49. Risinger JI, Hayes AK, Berchuck A & Barrett JC 1997 PTEN/MMAC1 mutations in endometrial cancers. Cancer Research 57 4736-4738.
50. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC & Berchuck A 1998 PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clinical Cancer Research 4 3005-3010.
51. Roshani L, Wedekind D, Szpirer J, Taib Z, Szpirer C, Beckman B, Rivière M, Hedrich HJ & Klinga-Levan K 2001 Genetic identification of multiple susceptibility genes involved in the development of endometrial carcinoma in a rat model. International Journal of Cancer 94 795-799.
52. Roshani L, Mallon P, Sjostrand E, Wedekind D, Szpirer J, Szpirer C, Hedrich HJ & Klinga-Levan K 2005 Genetic analysis of susceptibility to endometrial adenocarcinoma in the BDII rat model. Cancer Genetics and Cytogenetics 158 137-141.
53. Ryan AJ, Susil B, Jobling TW & Oehler MK 2005 Endometrial cancer. Cell and Tissue Research 322 53-61.
54. Saegusa M, Hashimura. M, Yoshida T & Okayasu I 2001 Beta-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. British Journal of Cancer 84 209-217.
55. Salvesen HB, Das S & Akslen LA 2000 Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroups of aggressive endometrial carcinomas wiht poor prognosis. Clinical Cancer Research 6 153-159.
56. Salvesen HB, Kumar R & Stefansson I 2005 Low frequency of BRAF and CDKN2A mutations in endometrial cancer. International Journal of Cancer 115 930-934.
57. Samuelson E, Levan K, Adamovic T, Levan G & Horvath G 2008 Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization. Cancer Genetics and Cytogenetics 181 25-30.
58. Sandles LG 1998 Familial endometrial adenocarcinoma. Clinical Obstetrics and Gynecology 41 167-171.
59. Sandles LG, Shulman LP, Elias S, Photopulos GJ, Smiley LM, Posten WM & Simpson JL 1992 Endometrial adenocarcinoma: genetic analysis suggesting heritable site-specific uterine cancer. Gynecologic Oncology 47 167-171.
60. Sjöling Å, Lindblom H, Samuelson E, Yamasaki Y, Watanabe TK, Tanigami A & Levan G 2001 Analysis of chromosomal aberrations involving chromosome 1q31q53 in a DMBA-induced rat fibrosarcoma cell line: amplification and overexpression of Jak2. Cytogenetics and Cell Genetics 95 202-209.
61. Sjöling A, Samuelson E, Adamovic T, Behboudi A, Röhme D & Levan G 2002 Recurrent allelic imbalance at the rat Pten locus in DMBA-induced fibrosarcomas. Genes, Chromosomes and Cancer 36 70-79.
62. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T et al. 1997 Identification of a candidate turnour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 15 356-362.
63. Strauli P & Haemmerli G 1984 The role of cancer cell motility in invasion. Cancer and Metastasis Reviews 3 127-141.
64. Tamura G, Ogasawara S, Nishizuka S, Sakata K, Maesawa C, Suzuki Y, Terashima M, Saito K & Satodate R 1996 Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Research 56 612-615.
65. Tanaka N & Taniguchi T 2000 The interferon regulatory factors and oncogenesis. Seminars in Cancer Biology 10 73-81.
66. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R & Ellenson LH 1997 Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Research 57 3935-3940.
67. Volk T, Geiger B & Raz A 1984 Motility and adhesive properties of high and low-metastatic murine neoplastic cells. Cancer Research 44 811-824.
68. Vollmer G 2003 Endometrial cancer: experimental models useful for studies on molecular aspects of endometrial cancer and carcinogenesis. Endocrine-Related Cancer 10 23-42.
69. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, Yamamoto H, Harada K, Meeker TC, List AF et al. 1993 Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science, 259 968-971.